Company intelligence / Profile preview

Beijing Wehand-Bio Pharmaceutical Co., Ltd.

Ownership: Private
Development stage: Other

Overview

The company has approved drugs in China (first approval in March 2020) and is conducting Phase 1 clinical trials for several compounds including a mulberry twig alkaloid for obesity and paclitaxel/WH-002 for HER2-negative breast cancer.

Therapeutic areas: OncologyEndocrinologyGastroenterologyNeurology
Modalities: Small molecule drugsHerbal medicine
Industry: Biotech

Drug pipeline

13 assets

ramulus mori alkaloids

12 more assets in the full pipeline.

Request access →

Partnerships

Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College

Beyond the preview

Go deeper on Beijing Wehand-Bio Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Wehand-Bio Pharmaceutical Co., Ltd..

Explore the full profile